Disease · MONDO_0009468
pseudotumor cerebri
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. pseudotumor cerebri. Diseases, record MONDO_0009468. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0009468
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- IIH, Idiopathic Intracranial Hypertension, benign intracran. hypt., benign intracranial hypertension, benign intracranial hypertension (disorder)
- Open Targets
Drugs13
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ACETAZOLAMIDE | CHEMBL20 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| EXENATIDE | CHEMBL414357 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FUROSEMIDE | CHEMBL35 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SEMAGLUTIDE | CHEMBL2108724 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AZD-4017 | CHEMBL2153191 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BEMIPARIN | CHEMBL3707365 | Oligosaccharide | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| DALTEPARIN SODIUM | CHEMBL1201460 | Oligosaccharide | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ENOXAPARIN | CHEMBL1201685 | Oligosaccharide | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ENOXAPARIN SODIUM | CHEMBL1201476 | Oligosaccharide | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| HEPARIN | CHEMBL4650299 | Oligosaccharide | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 13
See all 13 drugsTargets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SERPINC1 | Antithrombin-III | 5 | Antithrombin-III activator | Early phase 1 | https://conductscience.org/library/genes/462 | Drugs and targets |
| GLP1R | Glucagon-like peptide 1 receptor | 2 | Glucagon-like peptide 1 receptor agonist | Phase 3 | https://conductscience.org/library/genes/2740 | Drugs and targets |
| CA1 | Carbonic anhydrase 1 | 1 | Carbonic anhydrase I inhibitor | Phase 3 | https://conductscience.org/library/genes/759 | Drugs and targets |
| CA12 | Carbonic anhydrase 12 | 1 | Carbonic anhydrase XII inhibitor | Phase 3 | https://conductscience.org/library/genes/771 | Drugs and targets |
| CA2 | Carbonic anhydrase 2 | 1 | Carbonic anhydrase II inhibitor | Phase 3 | https://conductscience.org/library/genes/760 | Drugs and targets |
| CA4 | Carbonic anhydrase 4 | 1 | Carbonic anhydrase IV inhibitor | Phase 3 | https://conductscience.org/library/genes/762 | Drugs and targets |
| F10 | Coagulation factor X | 1 | Coagulation factor X inhibitor | Early phase 1 | https://conductscience.org/library/genes/2159 | Drugs and targets |
| HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | 1 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3290 | Drugs and targets |
| SLC12A1 | Solute carrier family 12 member 1 | 1 | Sodium-(potassium)-chloride cotransporter 2 inhibitor | Phase 3 | https://conductscience.org/library/genes/6557 | Drugs and targets |
Trials9
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01003639 | Idiopathic Intracranial Hypertension Treatment Trial | Phase 2/3 | 165 | 2018-12-12 | Idiopathic Intracranial Hypertension | ACETAZOLAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02017444 | Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. | Phase 2 | 31 | 2021-10-27 | Idiopathic Intracranial Hypertension | AZD-4017 | Its record names the disease | ClinicalTrials.gov |
| NCT05347147 | A Trial to Determine the Efficacy and Safety of Presendin in IIH | Phase 3 | 14 | 2024-04-24 | Idiopathic Intracranial Hypertension | EXENATIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03501966 | Surgical Idiopathic Intracranial Hypertension Treatment Trial | Phase 3 | 7 | 2022-06-16 | Idiopathic Intracranial Hypertension | ACETAZOLAMIDE, FUROSEMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT06919744 | Intracranial Venous Stenting Evaluation in Patients With Idiopathic Intracranial Hypertension in the Early Phase | Not applicable | 114 | Idiopathic Intracranial Hypertension (IIH) | ACETAZOLAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06945848 | Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide | Not applicable | 114 | Idiopathic Intracranial Hypertension (IIH) | ACETAZOLAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05707442 | Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE) | Phase 3 | 74 | Idiopathic Intracranial Hypotension, Venous Sinus Stenosis | ACETAZOLAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06361823 | Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment | Phase 3 | 74 | Idiopathic Intracranial Hypertension | SEMAGLUTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03963336 | Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension | Early phase 1 | 48 | Idiopathic Intracranial Hypertension | ACETAZOLAMIDE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Acetazolamide vs Sugar Pill: serious adverse events | 9 of 86 | 7 of 79 | 165 | NCT01003639 | Trial comparisons |
| AZD4017 (11b-HSD1 Inhibitor) vs Placebo: deaths from any cause | 0 of 17 | 0 of 14 | 31 | NCT02017444 | Trial comparisons |
| AZD4017 (11b-HSD1 Inhibitor) vs Placebo: serious adverse events | 0 of 17 | 1 of 14 | 31 | NCT02017444 | Trial comparisons |
Papers from its trials17
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 24756514 | RESULT | 1 | PubMed |
| 37740611 | DERIVED | 1 | PubMed |
| 36240084 | DERIVED | 1 | PubMed |
| 33098644 | DERIVED | 1 | PubMed |
| 28923789 | DERIVED | 1 | PubMed |
| 28492874 | DERIVED | 1 | PubMed |
| 28130349 | DERIVED | 1 | PubMed |
| 27694262 | DERIVED | 1 | PubMed |
| 26934136 | DERIVED | 1 | PubMed |
| 26778344 | DERIVED | 1 | PubMed |
1 to 10 of 17
See all 17 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0009468
GET https://conductscience.org/api/diseases/v1/MONDO_0009468/drugs